What is the global market size of Induced Pluripotent Stem Cells Production Market?

Global Induced Pluripotent Stem Cells Production Market size was valued at USD 1.10 billion in 2021 and is poised to grow from USD 1.22 billion in 2022 to USD 2.71 billion by 2030, at a CAGR of 10.5% during the forecast period (2023-2030).

Induced Pluripotent Stem Cells Production Market Size, Share, Growth Analysis, By Cell type(Hepatocytes, Fibroblasts, Keratinocytes, Neurons), By Process(Manual iPSC Production Process, Automated iPSC Production Process), By Workflow(Reprogramming, Cell Culture, Cell Characterization/Analysis, Engineering), By Product(Instruments/Devices, Automated Platforms, Consumables & Kits (Media, Kits), By Application(Drug Development, Regenerative Medicine, Toxicity Testing, Tissue Engineering), By End-user(Research & Academic Institutes, Biotechnology & Pharmaceutical Companies, Hospitals & Clinics), By Region - Industry Forecast 2024-2031

Report ID: SQMIG35H2225 | Region: Global | Published Date: June, 2024
Pages: 219 | Tables: 179 | Figures: 71

Induced Pluripotent Stem Cells Production Market News

In July 2022, Curi Bio, released the Mantaray platform for human-relevant 3D heart and skeletal engineered muscle tissue (EMT) contractility evaluation.

In May 2022, FUJIFILM Cellular Dynamics, Inc. Released Parkinson’s Disease iCell DopaNeurons providing LRRK2 and GBA mutations, which might be Parkinson's ailment chance-associated mutations

Induced Pluripotent Stem Cells Production Market Report Snapshots

License Type Top market research company in USA

File Type

$5,300

BUY NOW GET FREE SAMPLE

Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Global Induced Pluripotent Stem Cells Production Market size was valued at USD 1.22 billion in 2022 and is poised to grow from USD 1.35 billion in 2023 to USD 3 billion by 2031, growing at a CAGR of 10.5% during the forecast period (2024-2031).

The competitive landscape of the precipitated pluripotent stem mobile (iPSC) production marketplace is characterized through extreme competition among numerous outstanding players. These industry contributors are actively engaged in studies and improvement, focusing on enhancing iPSC production techniques and increasing their product portfolios. Competition is pushed with the aid of a quest for revolutionary answers to satisfy the increasing call for iPSCs across various applications, from drug discovery to regenerative remedy. 'Axl Bioscience Ltd. (UK)', 'Cynata Therapeutics Limited (UK)', 'Evotec SE (Germany)', 'Fate Therapeutics, Inc. (US)', 'FUJIFILM Cellular Dynamics, Inc. (US)', 'Ncardia (Belgium)', 'Pluricell Biotech (Spain)', 'REPROCELL USA, Inc. (US)', 'Sumitomo Dainippon Pharma Co., Ltd. (Japan)', 'Takara Bio, Inc. (Japan)', 'Thermo Fisher Scientific, Inc. (US)', 'ViaCyte, Inc. (US)'

One important key marketplace motive force in the worldwide pluripotent stem cell (iPSC) manufacturing market is the continuous improvements in regenerative medicinal drugs. IPSCs preserve immense capacity for developing personalised and powerful therapies for diverse medical situations, riding big investments in research and improvement. This progress fuels market boom by expanding the scope of iPSC applications, providing innovative remedy options, and attracting investments from pharmaceutical groups and healthcare establishments.

Emergence of iPSC-Based Disease Modeling :A main key market fashion in the global induced pluripotent stem cellular (iPSC) manufacturing marketplace is the increasing adoption of iPSCs for ailment modeling. Researchers and pharmaceutical businesses are making use of iPSC technology to create disorder-precise mobile traces, bearing in mind more accurate and customized modeling of various diseases, along with genetic disorders, neurodegenerative conditions, and cardiovascular illnesses. This trend not only aids in drug discovery and improvement but also paves the way for extra focused and powerful healing tactics, ultimately shaping the destiny of precision remedy.

North America has mounted itself as the dominating place within the global triggered pluripotent stem cell (iPSC) production market. This prominence is attributed to advanced healthcare infrastructure, enormous investments in biotechnology research, and a robust regulatory framework that encourages innovation. Leading international locations just like the United States and Canada house numerous biotechnology corporations and studies institutions that specialize in iPSC era. Moreover, a good reimbursement landscape and robust collaboration among academia and enterprise make contributions to North America's leadership in iPSC manufacturing.

Feedback From Our Clients

"We have purchased recently a report from SkyQuest Technology, and we are happy to inform you that this report was so useful and practical for our team. Skyquest Team was very active and our queries were followed up completely.It was amazing. "

- Mr. Ali Zali, Commercial Director, ICIIC Iran.

Induced Pluripotent Stem Cells Production Market News

Induced Pluripotent Stem Cells Production Market Report Snapshots

Want to customize this report?

FAQs

What is the global market size of Induced Pluripotent Stem Cells Production Market?

Who are the key vendors in the Induced Pluripotent Stem Cells Production Market?

What is the key driver of Induced Pluripotent Stem Cells Production Market?

What is the key market trend for Induced Pluripotent Stem Cells Production Market?

Which region accounted for the largest share in Induced Pluripotent Stem Cells Production Market?

Request Free Customization

Related Reports

Feedback From Our Clients

$5,300